Specify a stock or a cryptocurrency in the search bar to get a summary
Bioceltix S.A.
XI3Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use. Its products include BCX-CM-J, a stem-cell based biological drug for the treatment of degenerative joint lesions in dogs; BCX-CM-AD, a biological drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a biological drug candidate based on allogeneic mesenchymal stem cells for the treatment of arthritis in horses. The company was incorporated in 2018 and is based in Wroclaw, Poland. Address: Building III, Wroclaw, Poland, 51-317
Analytics
WallStreet Target Price
425.41 PLNP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures XI3
Dividend Analytics XI3
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History XI3
Stock Valuation XI3
Financials XI3
Results | 2019 | Dynamics |